XSHE
002727
Market cap937mUSD
Oct 08, Last price
10.75CNY
Name
Yixintang Pharmaceutical Group Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Yixintang Pharmaceutical Group Co., Ltd. is a prominent Chinese enterprise primarily managing an extensive network of pharmacies nationwide. The company's operations also encompass the production and retail of a diverse array of items, including raw medicinal ingredients, traditional Chinese herbal medicines, and various health and dietary supplements. Furthermore, it actively participates in pharmaceutical distribution. By January 31, 2020, its retail footprint spanned 7,205 outlets across numerous provinces and municipalities, such as Yunnan, Guizhou, Guangxi, Sichuan, Shanxi, Chongqing, Tianjin, Shanghai, and Qiong. Complementing its brick-and-mortar presence, Yixintang also conducts online sales. Established in 2000 with its headquarters in Kunming, China, the company adopted its current name, Yixintang Pharmaceutical Group Co., Ltd., in June 2019, having previously been called Yunnan Hongxiang Yixintang Pharmaceutical Co., Ltd.
Key people
Hongxian Ruan
Chairman of the Board, President · since 2019
Yong Zhang
Executive President, Director · since 2023
Donglei Xiao
Finance Director · since 2023
Guowei Ruan
Vice President · since 2025
Zhenghong Li
Vice President, Secretary of the Board · since 2019
Chunli Guo
Staff Elected Director · since 2025
Ning Jiang
Director · since 2025
Qiong Liu
Director · since 2010
Aixiang Ruan
Vice President, Director · since 2025
Lifang Liu
Independent Director · since 2025
Independent Director · since 2025
Qian Shi
Independent Director · since 2025
Headquarters & legal address
云南省昆明市经济技术开发区鸿翔路1号
昆明市, YN 100000
CN
昆明市, YN 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2019‑00 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||||
Revenues | |||||||||||||
Cost of revenue | |||||||||||||
Unusual Expense (Income) | |||||||||||||
NOPBT | |||||||||||||
NOPBT Margin | |||||||||||||
Operating Taxes | |||||||||||||
Tax Rate | |||||||||||||
NOPAT | |||||||||||||
Net income | |||||||||||||
Dividends | |||||||||||||
Dividend yield | |||||||||||||
Proceeds from repurchase of equity | |||||||||||||
BB yield | |||||||||||||
| Debt | |||||||||||||
Debt current | |||||||||||||
Long-term debt | |||||||||||||
Deferred revenue | |||||||||||||
Other long-term liabilities | |||||||||||||
Net debt | |||||||||||||
| Cash flow | |||||||||||||
Cash from operating activities | |||||||||||||
CAPEX | |||||||||||||
Cash from investing activities | |||||||||||||
Cash from financing activities | |||||||||||||
FCF | |||||||||||||
| Balance | |||||||||||||
Cash | |||||||||||||
Long term investments | |||||||||||||
Excess cash | |||||||||||||
Stockholders' equity | |||||||||||||
Invested Capital | |||||||||||||
ROIC | |||||||||||||
ROCE | |||||||||||||
| EV | |||||||||||||
Common stock shares outstanding | |||||||||||||
Price | |||||||||||||
Market cap | |||||||||||||
EV | |||||||||||||
EBITDA | |||||||||||||
EV/EBITDA | |||||||||||||
Interest | |||||||||||||
Interest/NOPBT | |||||||||||||